dc.creator | Martín Giménez, Virna Margarita | |
dc.creator | Mocayar Maron, Feres Jose | |
dc.creator | García, Sebastián | |
dc.creator | Mazzei, Luciana Jorgelina | |
dc.creator | Guevara, Manuel Alejandro | |
dc.creator | Yunes, Roberto Miguel Federico | |
dc.creator | Manucha, Walter Ariel Fernando | |
dc.date.accessioned | 2022-05-09T15:25:30Z | |
dc.date.accessioned | 2022-10-15T00:40:39Z | |
dc.date.available | 2022-05-09T15:25:30Z | |
dc.date.available | 2022-10-15T00:40:39Z | |
dc.date.created | 2022-05-09T15:25:30Z | |
dc.date.issued | 2021-03 | |
dc.identifier | Martín Giménez, Virna Margarita; Mocayar Maron, Feres Jose; García, Sebastián; Mazzei, Luciana Jorgelina; Guevara, Manuel Alejandro; et al.; Central nervous system, peripheral and hemodynamic effects of nanoformulated anandamide in hypertension; Medical Univ Bialystok; Advances In Medical Sciences; 66; 1; 3-2021; 72-80 | |
dc.identifier | 1896-1126 | |
dc.identifier | http://hdl.handle.net/11336/156928 | |
dc.identifier | 1898-4002 | |
dc.identifier | CONICET Digital | |
dc.identifier | CONICET | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4325869 | |
dc.description.abstract | Hypertensive lesions induce alterations at hemodynamic, peripheral, and central levels. Anandamide (N-arachidonoylethanolamine; AEA) protects neurons from inflammatory damage, but its free administration may cause central adverse effects. AEA controlled release by nanoformulations could reduce/eliminate its side effects. The present study aimed to evaluate the effects of nanoformulated AEA (nf-AEA) on systolic blood pressure (SBP), behavior, and central/peripheral inflammatory, oxidative, and apoptotic state in spontaneously hypertensive rats (SHR). Materials/methods: Male rats were used, both Wistar Kyoto (WKY) and SHR (n = 10 per group), with/without treatment with nf-AEA (obtained by electrospraying) at a weekly dose of 5 mg/kg IP for 4 weeks. SBP was measured and behavioral tests were performed. Inflammatory/oxidative markers were quantified at the central (brain cortex) and peripheral (serum) level. Results: SHR showed hyperactivity, low anxiety, and high concentrations of central/peripheral inflammatory/oxidative markers, also higher apoptosis of brain cortical cells compared to WKY. As opposed to this group, treatment with nf-AEA in SHR significantly reduced SBP, peripheral/central inflammatory/oxidative makers, and central apoptosis. Nf-AEA also increased neuroprotective mechanisms mediated by intracellular heat shock protein 70 (Hsp70), which were attenuated in untreated SHR. Additionally, nf-AEA reversed the abnormal behaviors observed in SHR without producing central adverse effects. Conclusions: Our results suggest protective properties of nf-AEA, both peripherally and centrally, through a signaling pathway that would involve the type I angiotensin II receptor, Wilms tumor transcription factor 1, Hsp70, and iNOS. Considering non-nf-AEA limitations, this nanoformulation could contribute to the development of new antihypertensive and behavioral disorder treatments associated with neuroinflammation. | |
dc.language | eng | |
dc.publisher | Medical Univ Bialystok | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S189611262030047X | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.advms.2020.12.003 | |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | ANANDAMIDE | |
dc.subject | HYPERTENSION | |
dc.subject | INFLAMMATION | |
dc.subject | NANOFORMULATION | |
dc.subject | OXIDATIVE STRESS | |
dc.title | Central nervous system, peripheral and hemodynamic effects of nanoformulated anandamide in hypertension | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:ar-repo/semantics/artículo | |
dc.type | info:eu-repo/semantics/publishedVersion | |